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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Huai Qi Huang (HQH) is a compound Chinese herbal medicine that con-
tains Trametes robiniophila murr, wolfberry fruit, and Polygonatum. In the present study,
we investigated the effects of HQH on patients with mild immunoglobulin A nephropathy (IgAN)
through a prospective randomized controlled study.
Methods: Forty-five adults diagnosed with IgAN according to renal pathology, who had hema-
turia or/and proteinuria ( 2 g/day), were randomly assigned to receive HQH or no treatment
for 12 weeks. Twenty-four hour urinary protein excretion and hematuria were measured at
Weeks 0, 4, 8, and 12. The rate of complete remission of proteinuria and hematuria was eval-
uated. Any adverse events induced by HQH were also observed during the treatment period.
Results: Twenty-four hour urinary protein excretion was significantly reduced by HQH treat-
ment compared with that in the control group at Weeks 8 and 12. A much higher rate of com-
plete remission of proteinuria was observed in the HQH group than in control group at Week 12.
HQH administration also obviously reduced the extent of hematuria compared with that in the
control group at Week 12. HQH treatment dramatically increased the rate of complete remis-
sion of hematuria compared with that in control group at Weeks 8 and 12. No obvious adverse
events caused by HQH were observed.
Conclusion: HQH could be a new conservative therapy for IgAN patients who cannot tolerate
steroids and immunosuppressive agents. The relapse rate after discontinuing treatment still
needs further investigation.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.t of Nephrology, Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Nangang
ublic of China.
ail.com (B. Li).
ight ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
3.10.019
Huai Qi Huang reduces proteinuria and hematuria 767Introduction
Immunoglobulin A nephropathy (IgAN) is a common primary
glomerulonephritis and also a leading cause of end-stage
renal disease (ESRD) throughout the world.1,2 The key
clinical manifestation of IgAN is microscopic or episodic
macroscopic hematuria and various degrees of proteinuria.
It has been reported that 10e25% of patients with IgAN will
proceed to ESRD within 10 years and 25e50% within 20
years.3,4 Risk factors associated with a poorer outcome are
impaired renal function at diagnosis, high blood pressure,
and urinary protein excretion.3 Proteinuria is the strongest
independent predictive factor leading to renal fibrosis and
renal failure in many kinds of glomerulonephritis and
chronic kidney disease.1,3,5e10 It has been recently recog-
nized that young persons with persistent isolated micro-
scopic hematuria have an increased risk for ESRD, mainly
secondary to primary glomerular diseases.11,12 Among these
causes, the association with progression to chronic kidney
disease is best established for IgA nephropathy and Alport
syndrome.11,12
There is still no universally accepted optimal thera-
peutic strategy for IgAN, especially IgAN with non-
nephrotic range proteinuria. Corticosteroid treatment is
controversial,13,14 and immunosuppressive agents such as
mycophenolate mofetil may be effective.15,16 Considering
their toxicity, they are not recommended for use in pa-
tients with mild proteinuria (< 1 g/day) and preserve
renal function according to KDOQI and KIDGO guidelines.
It is suggested that supportive therapy with inhibition of
the renin angiotensin system including angiotensin con-
verting enzyme inhibitor (ACEI) or angiotensin II receptor
blocker (ARB) should be used in these patients to control
hypertension and reduce proteinuria. However, we have
found that ACEI and ARB can only partly reduce protein-
uria; they cannot work on ameliorating hematuria. So far,
no ideal drugs have been found to reduce hematuria
effectively. Therefore, it is highly desirable to seek better
therapeutic strategies for IgAN patients that are not
suitable for treatment with steroids and immunosuppres-
sive agents.
Huai Qi Huang (HQH), a mixture of Chinese herbs, con-
tains Trametes robiniophila murr (Huaier), wolfberry fruit,
and Polygonatum. Aqueous extract of Huaier, the main
component of HQH, has been commonly used in China for
cancer complementary therapy in recent years.17 Some
evidence has shown that Huaier aqueous extract inhibits
proliferation of breast cancer cells by inducing apoptosis.18
Some studies have demonstrated that HQH can significantly
reduce proteinuria, prevent podocyte injury, ameliorate
tubulointerstitial damage and inhibit inflammatory cyto-
kine expression and macrophage infiltration in Adriamycin
nephrotic rats.19 Recently, Sun et al demonstrated that
Huaier exhibits antitumor potential and immunomodulatory
effects.20 HQH plays a key role in maintaining the balance
of cell and humoral immunity by decreased IgE level and
increasing cell numbers of CD3, CD4, and CD8 cells.20 HQH
is commonly used in children with repeated respiratory
infection, primary nephrotic syndrome or IgAN in China,
and has been shown to be effective in decreasing repeated
infection and reducing proteinuria and hematuria,21,22 butit is unclear whether it can work on adults with IgAN. In the
present study, a randomized controlled open labeled trial
was carried out to investigate the efficacy of HQH in the
reduction of proteinuria and hematuria in adults with mild
IgA nephropathy.Patients and methods
Patients
Forty-five IgAN adult patients recruited from May 2012 to
March 2013 from the Second Affiliated Hospital of Harbin
Medical University in China were enrolled in this prospec-
tive open-label randomized controlled trial. The study
protocol was approved by Ethics Committee of Harbin
medical university. All participating patients signed the
informed consent. To be included, eligible patients: (1)
were all confirmed IgAN by renal biopsy; (2) were IgA stage
I-II by pathology diagnosis according to Lee classification2;
(3) had hematuria or/and proteinuria ( 2 g/day); (4)
exhibited 24-hour urinary protein excretion < 2 g; and (5)
had not previously taken any steroids or immunosuppressive
drugs. Exclusion criteria were: (1) 24-hour urinary protein >
2 g/day; (2) serum creatinine > 133 mM; (3) active infec-
tion; (4) diabetes mellitus; (5) autoimmune disease; (6)
tumors; (7) chronic liver disease and liver function test
abnormalities; (8) blood pressure > 160/100 mmHg; and (8)
any other secondary glomerulonephritis.Study protocol
Forty-five patients were randomly assigned to the HQH
group or control group (without treatment). Patients in
HQH groups were given oral HQH granules 20 g three times/
day for 12 weeks. All patients with hypertension were
prescribed oral antihypertensive drugs within the blood
pressure tolerance range. The patients were asked to
measure 24-hour urinary protein excretion, hematuria, and
serum creatinine at Weeks 0, 4, 8, and 12. The blood
pressure and adverse events during the treatment period
were also recorded.Efficacy and safety assessments
In the present study, hematuria and 24-hour urinary protein
excretion was examined at different time points. The pri-
mary efficacy parameter was also evaluated by the rate of
complete remission of proteinuria and hematuria during the
treatment period. Complete remission of proteinuria was
defined as a value of urinary protein < 0.3 g/day and urine
dipstick for protein was negative. Complete remission of
hematuria was defined as < 10 red blood cells (RBC) per
high-power field (HPF) in urinary sediment. The extent of
microscopic hematuria was graded as: Grade 1: < 10 RBC/
HPF; Grade 2: 10e29.9 RBC/HPF; Grade 3: 30e59.9 RBC/
HPF; and Grade 4:  60 RBC/HPF according to previous
study.19
Figure 1 Patient profile. Forty-five patients with IgAN were randomly assigned to either the Huai Qi Huang (HQH) group (nZ 22)
or the control group (nZ 23). Seventeen patients showed persistent proteinuria (0.3e2.0 g/day) in the HQH group, and 18 patients
in the control group. Others presented isolated hematuria alone.
768 L.-T. Li et al.Statistical analysis
Continuous variables are described as mean  standard
deviation, and categorical variables are given as numbers
and percentages. An independent two-sample t test was
used in the comparison of means between groups, a paired
t test was used in analyzing changes within each group
during therapy, and the ManneWhitney U test was used for
nonparametric data. The incidence of remission was
compared using the Chi-square or Fisher exact test. A
p-value < 0.05 was considered statistically significant.Table 1 Baseline characteristics of the study population.
HQH group (n Z
Age (y) 30  11
Male/female 11/11
Urinary protein (g/d) 0.92  0.53
Urinary RBC numbers (/HPF) 66.5  36.5
Albumin (g/L) 43.3  4.4
Scr (mM) 78.1  16.5
Hypertension (n) 3
Systolic blood pressure (mm Hg) 121  15
Diastolic blood pressure (mm Hg) 72  9





Values are expressed as mean  standard deviation.
HPF Z high-power field; HQH Z Huai Qi Huang; RBC Z red blood ceResults
Baseline characteristics
Forty-five IgAN patients were recruited in this study, 22 of
them were assigned to the HQH group and the others were
in the control group (Fig. 1). They all completed the
treatment for 12 weeks and no patients dropped out of the
study. The basic data about patients are recorded in
Table 1. There was no difference between the two groups in22) Control group (n Z 23) p
32  9 0.589
10/13 0.554
0.92  0.60 0.983
67.6  28.8 0.905
42.7  4.7 0.657
73.3  16.6 0.335
2
120  12 0.952





lls; Scr Z serum creatinine.
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presented hypertension were given antihypertensive drugs
at the beginning of treatment.HQH significantly reduced proteinuria and
increased rate of complete remission of proteinuria
in mild IgAN patients
As is well known, proteinuria is an independent risk factor
associated with progression of IgAN. Proteinuria was seen
in 35 patients in this study: 17 patients in the HQH group
and 18 in the control group (p Z 1.000; Fig. 1). Twenty-
four hour urinary protein excretion in the HQH group
significantly lowered than that in the control group at 8
weeks and 12 weeks (Fig. 2A). Furthermore, the rate of
complete remission of proteinuria in the HQH group
(82.4%) was significantly higher than that in control group
(33.3%, p Z 0.006; Fig. 2B). The data demonstrate that
treatment with HQH can significantly reduce proteinuria in
mild IgAN.Figure 2 Twenty-four hour urinary protein excretion (UPE)
and complete remission rate of proteinuria at Weeks 4, 8, and
12. The patients who presented only isolated hematuria were
excluded in this statistic. (A) Twenty-four hour UPE was
significantly lower than that in untreated group at 8 weeks
(p Z 0.012) and 12 weeks (p Z 0.014). (B) The rate of com-
plete remission of proteinuria was significantly increased at 12
weeks compared with that in control group (p Z 0.006).
HQH Z Huai Qi Huang. * p < 0.05 versus control group.
** p < 0.01 versus control group.HQH significantly ameliorated hematuria and
increased the rate of complete remission of
hematuria in mild IgAN patients
The grade of hematuria of two groups before and after
treatment is shown in Fig. 3A. There was a striking reduc-
tion of hematuria after taking HQH, compared with control
group (Fig. 3A). As shown in Fig. 3B, the average grade of
hematuria was 3.27 before treatment and was down to 1.41
at 12 weeks in the HQH group. The grade of hematuria in
the HQH group was greatly ameliorated compared with that
in control group, which was 2.86 at 12 weeks (p < 0.001).
Ten patients (45.5%) at 8 weeks and 14 patients (63.6%) at
12 weeks achieved complete remission of hematuria in the
HQH group, which was significantly higher than that in
control group (n Z 2, 8.7%, at 8 weeks, p Z 0.007; and
(nZ 3, 13.0%, at 12 weeks, pZ 0.001), as shown in Fig. 3C.
The data show that HQH administration can significantly
ameliorate hematuria in mild IgAN.Figure 3 Hematuria grade and complete remission rate of
hematuria. (A) The hematuria grade from the two groups
before and after treatment for 12 weeks. (B) The extent of
hematuria was significantly reduced at 12 weeks, compared
with that in control group (p < 0.001). (C) The rate of complete
remission of hematuria was significantly increased at 8 weeks
(pZ 0.007) and 12 weeks compared with that in control group
(p Z 0.001). HQH Z Huai Qi Huang. * p < 0.05 versus control
group. ** p < 0.01 versus control group.
Table 2 Comparison of serum creatinine (Scr) and blood pressure at baseline and 12 weeks between the two groups.
HQH group (n Z 22) Control group (n Z 23) p
Baseline 12 wk Baseline 12 wk
Scr (mM) 78.1  16.5 70.3  16.4 71.4  16.7 70.9  14.0 0.903
SBP (mmHg) 121  15 118  11.5 107  13 111  12 0.666
DBP (mmHg) 72  9 66  9 70  8 67  6 0.706
Values are expressed as mean  standard deviation.
DBP Z diastolic blood pressure; HQH Z Huai Qi Huang; SBP Z systolic blood pressure.
770 L.-T. Li et al.Adverse events and compliance
There were no adverse events associated with HQH apart
from one patient with mild diarrhea in the treatment
period. There were no differences in blood pressure or
serum creatinine compared with the baseline in either
group (Table 2 and Fig. 4). Patients treated with HQH
showed a good compliance throughout our study.Discussion
IgAN is characterized by mesangial deposition of pathogenic
polymeric IgA1, proliferation of mesangial cells, increased
synthesis of the extracellular matrix, and infiltration of
macrophages, monocytes, and T cells.23,24 IgAN is increas-
ingly considered an immune complex deposition disease,
with immune abnormalities. Multiple cytokines andFigure 4 The blood pressure at baseline and 12 weeks. (A) Systol
12 weeks in both groups. (B) Diastolic blood pressure (DBP) chan
HQH Z Huai Qi Huang.chemokines are involved in glomerular and renal tubular
injury in patients with IgAN.25e27 Despite the available
therapeutic options, 35e40% of patients with IgAN still
develop ESRD and require dialysis and renal trans-
plantation. Of the known of risk factors, one of the most
important and potentially modifiable is proteinuria, which
is associated with outcome improvement.5 Registry data
suggest a threshold of proteinuria of 1 g/day, below which
there is significantly improved renal survival. A study
showed that IgAN patients with proteinuria < 0.5 g/day
have better prognosis than those with proteinuria of
0.5e1.0 g/day. An optimal goal of antiproteinuric therapy
for patients with IgAN is < 0.5 g/day.3 ACEI and ARB have
been widely used in IgAN and have been demonstrated
effective. However, a significant proportion of patients do
not achieve complete remission of proteinuria despite
maximal doses of ACEI or ARB.28e30 There is increasing ev-
idence that isolated hematuria, a forgotten chronic kidneyic blood pressure (SBP) changes before and after treatment for
ges before and after treatment for 12 weeks in both groups.
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IgAN.11,12 So far, no drugs have obvious benefit on hema-
turia except steroids and immunosuppressive agents, which
are not recommended to treat mild IgAN because of side
effects and toxicity. Therefore, seeking a new therapy is
highly desirable. With this purpose, we tested the hypoth-
esis that in mild IgAN patients with hematuria and/or pro-
teinuria not fully controlled with renin-angiotensin system
inhibitor (RASI) and other antihypertensive drugs, the
amelioration could be obtained by the antiproliferation and
immunomodulating properties of HQH.
In our randomized controlled trial study, we observed
that treatment with HQH for 12 weeks could significantly
reduce hematuria and 24-hour urinary protein excretion,
and increase the rate of complete remission of proteinuria
and hematuria of patients with mild IgAN. In addition, no
severe adverse events were observed.
HQH is primarily composed of Huaier, wolfberry fruit,
and Polygonatum. Huaier, which contains six kinds of
monosaccharide and 18 kinds of amino acid, is a biological
response modifier that can stimulate many elements of the
immune system to enhance immunity. The wolfberry fruit
and Polygonatum provide synergetic effects. Aqueous
extract of Huaier is used for cancer complementary therapy
in China, and its immunomodulatory effects have been
shown.31,32 IgAN is also a kind of proliferative glomerulo-
nephritis, which might explain why HQH is effective in
treating IgAN. Recently, Zhu et al found evidence that HQH
has protective effects on Adriamycin nephrosis in rats. They
found that HQH can significantly reduce proteinuria, pre-
vent podocyte injury, and ameliorate tubulointerstitial
damage by inhibiting inflammatory cytokine expression and
macrophage infiltration.19 There is an imbalance between T
helper 1 and T helper 2 cells in IgAN.26 Some studies have
considered that HQH can adjust this imbalance to achieve
treatment of IgAN. The probable reasons for amelioration
of proteinuria and hematuria achieved by HQH adminis-
tration are the antiproliferation, prevention of podocyte
injury, and anti-inflammatory effects, as suggested by the
significant reduction in hematuria, a known marker of
inflammation in IgAN patients.
In the present study, we found that urinary protein
excretion had a downward tendency after using HQH,
achieving a significant difference between two groups at 8
weeks and 12 weeks. This indicates that HQH was able
quickly and effectively to reduce the proteinuria of pa-
tients with IgAN. There was also a higher rate of complete
remission of proteinuria was calculated after HQH treat-
ment. So far, drugs to reduce hematuria have rarely been
reported. In this study, we found that HQH not only could
reduce the proteinuria, but also obviously diminish the
hematuria. The average grade and complete remission of
hematuria significantly abated in HQH group compared with
those in the control group. Therefore, HQH plays a
distinctive role in ameliorating the hematuria of IgAN. No
adverse event induced by oral HQH treatment was observed
during the treatment period.
The present study is limited by the small sample size,
without placebo and short follow-up. We need to observe
the alterations of proteinuria and hematuria after dis-
continuing HQH. Follow-up time needs to be longer in
future studies. We enrolled the patients with normal kidneyfunction, and mild to moderate proteinuria, so there was
no evidence of whether the HQH is effective on severe IgAN
patients. This needs to be further investigated.
In this study, patients were offered HQH when proved to
be IgAN by renal biopsy. Some evidence has demonstrated
that a minority of adult IgAN patients may have a sponta-
neous remission of hematuria and proteinuria.33,34 This
might explain why about 33.3% complete remission of pro-
teinuria and 13% complete remission of hematuria were
observed in control group at the present study.
In conclusion, HQH is an effective and well-tolerated
therapeutic strategy that could increase the rate of com-
plete remission of proteinuria and hematuria in mild IgAN
patients. It could be a new conservative therapy for IgAN
patients who cannot tolerate steroids and immunosup-
pressive agents. The relapse rate after discontinuing
treatment needs to be further investigated.Acknowledgments
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